Profile data is unavailable for this security.
About the company
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
- Revenue in USD (TTM)86.55m
- Net income in USD-24.61m
- Incorporated2015
- Employees100.00
- LocationY-mAbs Therapeutics Inc230 PARK AVENUE, SUITE 3350NEW YORK 10169United StatesUSA
- Phone+1 (212) 847-9841
- Fax+1 (302) 655-5049
- Websitehttps://www.ymabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Savara Inc | 0.00 | -75.29m | 653.46m | 37.00 | -- | 5.39 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Alumis Inc | 0.00 | -189.03m | 653.93m | 128.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.57 | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
| Korro Bio Inc | 0.00 | -92.22m | 654.64m | 92.00 | -- | 3.30 | -- | -- | -30.51 | -30.51 | 0.00 | 21.34 | 0.00 | -- | -- | 0.00 | -56.06 | -31.55 | -59.82 | -36.48 | -- | -- | -- | -365.87 | -- | -167.13 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Astria Therapeutics Inc | 0.00 | -93.24m | 666.95m | 59.00 | -- | 2.58 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Sana Biotechnology Inc | 0.00 | -244.90m | 668.51m | 328.00 | -- | 1.97 | -- | -- | -1.15 | -1.15 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -36.94 | -38.99 | -42.11 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 689.94m | 100.00 | -- | 7.24 | -- | 7.97 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 698.16m | 28.00 | -- | 2.41 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Exscientia PLC (ADR) | 27.16m | -167.45m | 703.15m | 483.00 | -- | 1.81 | -- | 25.89 | -1.31 | -1.31 | 0.2137 | 3.01 | 0.042 | -- | 26.88 | 56,234.72 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 710.10m | 80.00 | -- | 3.13 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Arbutus Biopharma Corp | 6.74m | -76.70m | 710.59m | 73.00 | -- | 6.65 | -- | 105.40 | -0.4259 | -0.4259 | 0.0374 | 0.5643 | 0.0451 | -- | 3.57 | 92,356.16 | -51.29 | -52.62 | -59.50 | -58.11 | -- | -- | -1,137.65 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Humacyte Inc | 0.00 | -139.66m | 722.67m | 183.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | -0.237 | 0.00 | -- | -- | 0.00 | -91.17 | -- | -100.75 | -- | -- | -- | -- | -- | -- | -40.08 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 723.77m | 107.00 | -- | 2.30 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| MBX Biosciences Inc | 0.00 | -47.20m | 729.77m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Paradigm BioCapital Advisors LPas of 30 Jun 2024 | 3.87m | 8.68% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 3.30m | 7.40% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.61m | 5.86% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.04m | 4.57% |
| Polar Capital LLPas of 30 Jun 2024 | 1.83m | 4.11% |
| Cormorant Asset Management LPas of 30 Jun 2024 | 1.45m | 3.25% |
| D. E. Shaw & Co. LPas of 30 Jun 2024 | 926.46k | 2.08% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 804.61k | 1.81% |
| Geode Capital Management LLCas of 30 Jun 2024 | 765.64k | 1.72% |
| Pictet Asset Management SAas of 30 Jun 2024 | 659.67k | 1.48% |
